Comment on: Patients' preferences for anti-osteoporosis drug treatment: a cross-European discrete choice experiment: reply

Mickaël Hiligsmann; Benedict G Dellaert; Verity Watson; Annelies Boonen

doi:10.1093/rheumatology/kex430

Comment on: Patients' preferences for anti-osteoporosis drug treatment: a cross-European discrete choice experiment: reply

Mickaël Hiligsmann, Benedict G Dellaert, Verity Watson, Annelies Boonen

Health Economics Research Unit

Research output: Contribution to journal › Comment/debate › peer-review

2 Citations (Scopus)

Abstract

We are grateful to Dr Armstrong [1] for sharing his views and concerns about our recent paper that elicited patients’ preferences for osteoporosis drug treatment using a cross-European discrete-choice experiment (DCE) [2].

Original language	English
Pages (from-to)	584-585
Number of pages	2
Journal	Rheumatology
Volume	57
Issue number	3
Early online date	28 Nov 2017
DOIs	https://doi.org/10.1093/rheumatology/kex430
Publication status	Published - 30 Mar 2018

Bibliographical note

Funding: No specific funding was received from any funding bodies in the public, commercial or not-for-profit sectors to carry out the work described in this manuscript.

Keywords

Journal Article

Access to Document

10.1093/rheumatology/kex430Licence: Unspecified

Cite this

@article{270e2c2832384791bdc14d8276d2aeaf,

title = "Comment on: Patients' preferences for anti-osteoporosis drug treatment: a cross-European discrete choice experiment: reply",

abstract = "We are grateful to Dr Armstrong [1] for sharing his views and concerns about our recent paper that elicited patients{\textquoteright} preferences for osteoporosis drug treatment using a cross-European discrete-choice experiment (DCE) [2].",

keywords = "Journal Article",

author = "Micka{\"e}l Hiligsmann and Dellaert, {Benedict G} and Verity Watson and Annelies Boonen",

note = "Funding: No specific funding was received from any funding bodies in the public, commercial or not-for-profit sectors to carry out the work described in this manuscript.",

year = "2018",

month = mar,

day = "30",

doi = "10.1093/rheumatology/kex430",

language = "English",

volume = "57",

pages = "584--585",

journal = "Rheumatology",

issn = "1462-0324",

publisher = "Oxford University Press",

number = "3",

}

TY - JOUR

T1 - Comment on: Patients' preferences for anti-osteoporosis drug treatment: a cross-European discrete choice experiment: reply

AU - Hiligsmann, Mickaël

AU - Dellaert, Benedict G

AU - Watson, Verity

AU - Boonen, Annelies

N1 - Funding: No specific funding was received from any funding bodies in the public, commercial or not-for-profit sectors to carry out the work described in this manuscript.

PY - 2018/3/30

Y1 - 2018/3/30

N2 - We are grateful to Dr Armstrong [1] for sharing his views and concerns about our recent paper that elicited patients’ preferences for osteoporosis drug treatment using a cross-European discrete-choice experiment (DCE) [2].

AB - We are grateful to Dr Armstrong [1] for sharing his views and concerns about our recent paper that elicited patients’ preferences for osteoporosis drug treatment using a cross-European discrete-choice experiment (DCE) [2].

KW - Journal Article

U2 - 10.1093/rheumatology/kex430

DO - 10.1093/rheumatology/kex430

M3 - Comment/debate

C2 - 29194497

SN - 1462-0324

VL - 57

SP - 584

EP - 585

JO - Rheumatology

JF - Rheumatology

IS - 3

ER -

Comment on: Patients' preferences for anti-osteoporosis drug treatment: a cross-European discrete choice experiment: reply

Abstract

Bibliographical note

Keywords

Access to Document

Fingerprint

Cite this